Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients

Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients

Background

Delayed graft function (DGF) after kidney transplantation can lead to negative patient and allograft outcomes. Prolonged DGF is linked to worse graft outcomes. The relationship between posttransplant serum β2-microglobulin (B2M) and DGF recovery is not well understood.

Methods

All kidney-only transplant recipients with DGF from the E-DGF trial were included. DGF duration was defined as the time between transplant and the last dialysis session. The association of standardized serum creatinine (Scr) and B2M on postoperative Days 1-7 with DGF recovery was analyzed.

Results

97 recipients with DGF were included, with a mean DGF duration of 11.0 ± 11.2 days. Higher Scr was not associated with DGF duration, but higher standardized B2M was linked to a prolonged DGF duration. This association remained even after adjusting for baseline characteristics.

Conclusion

B2M is more strongly associated with DGF recovery than Scr. Posttransplant B2M may be an important biomarker to monitor during DGF.

Trial Registration

ClinicalTrials.gov identifier: NCT03864926

Practical Solutions and Value

Clinical trials are crucial for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into an easily accessible knowledge base for clinicians. Streamlining operations is essential in today’s healthcare environment, and our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routines.